madman
Super Moderator
- Summary
- Yale's Dr. Ania Jastreboff on food noise, why obesity is not a willpower failure, and how retatrutide differs from semaglutide and tirzepatide.
The Downsized sits down with Dr. Ania Jastreboff, Yale professor, endocrinologist, obesity medicine physician-scientist, director of the Yale Obesity Research Center, and one of the leading researchers studying the next generation of obesity medications.
In the first half of this special two-part conversation, Christopher and Laraine Durham talk with Dr. Jastreboff about what obesity science is teaching us about weight, hunger, food noise, biology, and why obesity is not a failure of willpower.
They also dive into retatrutide, the highly anticipated triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon. Dr. Jastreboff discusses the TRIUMPH-1 trial and explains why researchers are interested in much more than weight loss, including the potential effects of glucagon activity on liver fat and metabolic health.
The conversation explores:
• How retatrutide differs from semaglutide and tirzepatide
• Why the next generation of obesity medications will go far beyond GLP-1s
• The role of amylin drugs such as cagrilintide and combinations such as CagriSema
• Why obesity may eventually require many different classes of medication
• Dr. Jastreboff’s “enough point” theory and how the brain regulates body fat
• Why the modern environment can push the body toward storing more fat
• Why biology drives far more of our eating behavior than most people realize
• What GLP-1 medications have taught researchers about food noise
• Why hunger returning does not necessarily mean a medication has stopped working
• What happens when patients reach a weight-loss plateau
• How to think about maintenance and finding the right weight for your body
• Why BMI and the number on the scale cannot tell the entire story
• Why treating obesity before diabetes, cardiovascular disease, sleep apnea, or other complications develop matters